SFX by Ex Libris Inc.

Title:	Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
Source:	Blood [0006-4971] Bonifazi, Francesca yr:2001

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Burchert, A. "Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia." Journal of clinical oncology 28.8 (2010): 1429-1435.
description	2.	Wu, E. "A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37." Virology 279.1 (2001): 78-89.
description	3.	Simonsson, B. "Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia." Blood 118.12 (2011): 3228-3235.
description	4.	Le Cesne, A. "Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial." Lancet oncology 11.11 (2010): 942-9.
description	5.	Ernst, P. "IFN-alpha wakes up sleeping hematopoietic stem cells." Nature Medicine 15.6 (2009): 612-613.
description	6.	Gruber, Andreas X. "Detection of Drug-Resistant Clones in Chronic Myelogenous Leukemia Patients during Dasatinib and Nilotinib Treatment." Clinical Chemistry 56.3 (2010): 469-473.
description	7.	Toikkanen, U. "Riskianalyysista apua glaukoomapotilaiden tunnistamiseen." SUOMEN LAAKARILEHTI 63,.7, (2008): 604-.
description	8.	Etienne, G. "Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia." Journal of clinical oncology 35.3 (2016): 298-305.
description	9.	Fava, C. "Chronic Myeloid Leukemia: State of the Art in 2012." Current oncology reports 14.5 (2012): 1-8.
description	10.	Ross, Ross M. "Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR." Leukemia 24.10 (2010): 1719-1724.
description	11.	Singbrant, S. "The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease." Haematologica (2014).
description	12.	Larocca, A. "Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide." Blood 119.4 (2011): 933-939.
description	13.	Barbui, T. "How to manage thrombosis in myeloproliferative neoplasms." Current opinion in oncology 23.6 (2011): 654-658.
description	14.	Kiladjian, J. "The renaissance of interferon therapy for the treatment of myeloid malignancies." Blood 117.18 (2011): 4706-4715.
description	15.	Castelli, M Gary I C. "Comparing the Efficacy and Tolerability of a New Daily Oral Vitamin B-12 Formulation and Intermittent Intramuscular Vitamin B-12 in Normalizing Low Cobalamin Levels: A Randomized, Open-Label, Parallel-Group Study." Clinical therapeutics 33.3 (2011): 358-371.
description	16.	Naldini, L. "Ex vivo gene transfer and correction for cell-based therapies." Nature reviews. Genetics 12.5 (2011): 301-15.
description	17.	Giannini, Edoardo G. "Predictive Factors for Response to Peginterferon-Alpha and Ribavirin Treatment of Chronic HCV Infection in Patients Aged 65 Years and More." Digestive diseases and sciences 55.11 (2010): 3193-3199.
description	18.	Sabnis, A. "Oncogenic Kras initiates leukemia in hematopoietic stem cells." PLoS biology 7.3 (2009): -548.
description	19.	Larson, RA. "Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia." Leukemia 23.6 (2009): 1054-1061.
description	20.	Hughes, T. "Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results." Blood 108.1 (2006): 28-37.